. 2016 Nov 2;21(11):1462. doi: 10.3390/molecules21111462

Table 1.

In vitro EGFR tyrosine kinases (wild-type and L858R/T790M mutation) activities ^a.

Compounds	EGFR (IC₅₀, nM) ^b		SI(WT:L858R/T790M)
Compounds	WT	L858R/T790M	SI(WT:L858R/T790M)
DY3002	448.7	0.71	632.0
Rociletinib	460.2	21.5	21.4
Osimertinib	482.3	11.8	40.9
Gefitinib	15.5	823.3	--

^a Data represent the mean of at least three separate experiments; ^b Concentration needed to inhibit the autophosphorylation of the cytoplasmic domain of EGFR by 50%, as calculated using GraphPad Prim version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).